The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended Study
Background and objectives: Anti-Tumor necrosis factor agents are among the most effective therapies for Rheumatoid Arthritis, however, their optimal use is yet to be determined.In this 5 year open-labeled study attempted remission induction using standard therapy with infliximab in patients with po...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kurdistan Higher Council Of Medical Specialties
2023-03-01
|
| Series: | Advanced Medical Journal |
| Subjects: | |
| Online Access: | https://amj.khcms.edu.krd/index.php/main/article/view/140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850201541028347904 |
|---|---|
| author | Niaz Jawad Albarzinji |
| author_facet | Niaz Jawad Albarzinji |
| author_sort | Niaz Jawad Albarzinji |
| collection | DOAJ |
| description |
Background and objectives: Anti-Tumor necrosis factor agents are among the most effective therapies for Rheumatoid Arthritis, however, their optimal use is yet to be determined.In this 5 year open-labeled study attempted remission induction using standard therapy with infliximab in patients with poor response to ordinary disease modifying anti-Rheumatic drugs.
Methods: Patients responding inadequately to methotrexate and at least one other disease-modi- fying anti-rheumatic drug were enrolled into a 24-week, controlled study with infliximab plus methotrexate or placebo plus methotrexate and some were enrolled in a subsequent open-label extension. The efficacy were evaluated by measuring the disease activity by using DAS-28(disease activity score in 28 points) and functional evaluation by using the health assessment questioner (HAQ).
Results: Among 250 patients in the original trial, 220 received at least one dose of infliximab and were evaluated. At the time of analysis 160/ 220 (72.7%) patients had remained in the study and received treatment for a mean of 4.5 years. Withdrawals were for lack of efficacy (24%), adverse events (36%), and other reasons (50%). In 160 patients who completed 5 years treatment efficacy achieved in 6 months was maintained at 5 years. 45% achieved clinical remission (DAS28<2.6), and 27% had no physical function abnormalities (HAQ=0). Results were similar for 160 patients who received treatment for 3-5 years.
Conclusions: In patients with persistently active Rheumatoid Arthritis despite Methotraxate therapy, repeated doses of infliximab in combination with methotraxate provided clinical remissions with functional and quality of life benefits were sustained.
|
| format | Article |
| id | doaj-art-538d181aac0b4e079faf342107032e18 |
| institution | OA Journals |
| issn | 2958-8979 2957-3580 |
| language | English |
| publishDate | 2023-03-01 |
| publisher | Kurdistan Higher Council Of Medical Specialties |
| record_format | Article |
| series | Advanced Medical Journal |
| spelling | doaj-art-538d181aac0b4e079faf342107032e182025-08-20T02:11:58ZengKurdistan Higher Council Of Medical SpecialtiesAdvanced Medical Journal2958-89792957-35802023-03-014110.56056/amj.2018.33141The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended StudyNiaz Jawad Albarzinji0Hawler Medical University/ College of Medicine Background and objectives: Anti-Tumor necrosis factor agents are among the most effective therapies for Rheumatoid Arthritis, however, their optimal use is yet to be determined.In this 5 year open-labeled study attempted remission induction using standard therapy with infliximab in patients with poor response to ordinary disease modifying anti-Rheumatic drugs. Methods: Patients responding inadequately to methotrexate and at least one other disease-modi- fying anti-rheumatic drug were enrolled into a 24-week, controlled study with infliximab plus methotrexate or placebo plus methotrexate and some were enrolled in a subsequent open-label extension. The efficacy were evaluated by measuring the disease activity by using DAS-28(disease activity score in 28 points) and functional evaluation by using the health assessment questioner (HAQ). Results: Among 250 patients in the original trial, 220 received at least one dose of infliximab and were evaluated. At the time of analysis 160/ 220 (72.7%) patients had remained in the study and received treatment for a mean of 4.5 years. Withdrawals were for lack of efficacy (24%), adverse events (36%), and other reasons (50%). In 160 patients who completed 5 years treatment efficacy achieved in 6 months was maintained at 5 years. 45% achieved clinical remission (DAS28<2.6), and 27% had no physical function abnormalities (HAQ=0). Results were similar for 160 patients who received treatment for 3-5 years. Conclusions: In patients with persistently active Rheumatoid Arthritis despite Methotraxate therapy, repeated doses of infliximab in combination with methotraxate provided clinical remissions with functional and quality of life benefits were sustained. https://amj.khcms.edu.krd/index.php/main/article/view/140InfleximabMethotroxateRheumatoid Arthritis |
| spellingShingle | Niaz Jawad Albarzinji The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended Study Advanced Medical Journal Infleximab Methotroxate Rheumatoid Arthritis |
| title | The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended Study |
| title_full | The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended Study |
| title_fullStr | The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended Study |
| title_full_unstemmed | The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended Study |
| title_short | The Efficacy of Infliximab Plus Methotrexate in Patients with Active Rheumatoid Arthritis in North of Iraq: 5 year Extended Study |
| title_sort | efficacy of infliximab plus methotrexate in patients with active rheumatoid arthritis in north of iraq 5 year extended study |
| topic | Infleximab Methotroxate Rheumatoid Arthritis |
| url | https://amj.khcms.edu.krd/index.php/main/article/view/140 |
| work_keys_str_mv | AT niazjawadalbarzinji theefficacyofinfliximabplusmethotrexateinpatientswithactiverheumatoidarthritisinnorthofiraq5yearextendedstudy AT niazjawadalbarzinji efficacyofinfliximabplusmethotrexateinpatientswithactiverheumatoidarthritisinnorthofiraq5yearextendedstudy |